Q2 2016 13F Holders as of 30 Jun 2016
-
Type / Class
-
Equity / Common Stock, $0.0001 Par Value Per Share
-
Shares outstanding
-
107,800,271
-
Number of holders
-
139
-
Total 13F shares, excl. options
-
30,535,006
-
Shares change
-
+1,039,155
-
Total reported value, excl. options
-
$1,185,218,083
-
Value change
-
+$46,613,508
-
Put/Call ratio
-
44.6%
-
Number of buys
-
84
-
Number of sells
-
-44
-
Price
-
$38.82
Significant Holders of Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) as of Q2 2016
164 filings reported holding ITCI - Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share as of Q2 2016.
Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) has 139 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 30,535,006 shares
of 107,800,271 outstanding shares and own 28.3% of the company stock.
Largest 10 shareholders include FMR LLC (6,484,897 shares), VANGUARD GROUP INC (2,355,713 shares), TimesSquare Capital Management, LLC (1,619,875 shares), JENNISON ASSOCIATES LLC (1,279,597 shares), BlackRock Advisors LLC (1,257,910 shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (1,100,000 shares), BlackRock Fund Advisors (1,043,100 shares), Redmile Group, LLC (971,565 shares), ORBIMED ADVISORS LLC (885,400 shares), and WASATCH ADVISORS INC (811,812 shares).
This table shows the top 139 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.